Ryan Deschner
Stock Analyst at Raymond James
(3.86)
# 659
Out of 5,240 analysts
21
Total ratings
83.33%
Success rate
78.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ryan Deschner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IFRX InflaRx | Upgrades: Strong Buy | $7 → $9 | $2.38 | +278.15% | 1 | May 13, 2026 | |
| APLS Apellis Pharmaceuticals | Downgrades: Market Perform | n/a | $41.03 | - | 3 | Apr 1, 2026 | |
| PVLA Palvella Therapeutics | Upgrades: Strong Buy | $92 → $143 | $118.97 | +20.20% | 2 | Nov 19, 2025 | |
| TVRD Tvardi Therapeutics | Downgrades: Market Perform | n/a | $3.96 | - | 2 | Oct 14, 2025 | |
| LQDA Liquidia | Maintains: Strong Buy | $33 → $41 | $59.30 | -30.86% | 4 | Aug 13, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Strong Buy | $29 → $27 | $15.08 | +79.05% | 3 | Aug 8, 2025 | |
| ARDX Ardelyx | Maintains: Outperform | $11 → $12 | $6.46 | +85.76% | 2 | Aug 5, 2025 | |
| VKTX Viking Therapeutics | Maintains: Strong Buy | $125 → $122 | $31.71 | +284.74% | 1 | Jul 24, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Strong Buy | $26 → $28 | $7.94 | +252.64% | 3 | Jan 14, 2025 |
InflaRx
May 13, 2026
Upgrades: Strong Buy
Price Target: $7 → $9
Current: $2.38
Upside: +278.15%
Apellis Pharmaceuticals
Apr 1, 2026
Downgrades: Market Perform
Price Target: n/a
Current: $41.03
Upside: -
Palvella Therapeutics
Nov 19, 2025
Upgrades: Strong Buy
Price Target: $92 → $143
Current: $118.97
Upside: +20.20%
Tvardi Therapeutics
Oct 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $3.96
Upside: -
Liquidia
Aug 13, 2025
Maintains: Strong Buy
Price Target: $33 → $41
Current: $59.30
Upside: -30.86%
Trevi Therapeutics
Aug 8, 2025
Maintains: Strong Buy
Price Target: $29 → $27
Current: $15.08
Upside: +79.05%
Ardelyx
Aug 5, 2025
Maintains: Outperform
Price Target: $11 → $12
Current: $6.46
Upside: +85.76%
Viking Therapeutics
Jul 24, 2025
Maintains: Strong Buy
Price Target: $125 → $122
Current: $31.71
Upside: +284.74%
ARS Pharmaceuticals
Jan 14, 2025
Maintains: Strong Buy
Price Target: $26 → $28
Current: $7.94
Upside: +252.64%